FOLH1 and prostate carcinoma: For example, by targeting prostate‐specific membrane antigen (PSMA), alpha‐emitting radioimmunoconjugates such as Ac‐225‐PSMA‐617 have demonstrated success in treating metastatic castration‐resistant prostate cancer.47